Immune-mediated inflammatory diseases (IMIDs) are referred to as highly disabling chronic
diseases affecting different organs and systems. Inappropriate or excessive immune …

Type 1 diabetes is an autoimmune disease characterised by the destruction of insulin
producing beta cells in the pancreas. Whilst it remains unclear what the original triggering …

Background Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved
by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) …

We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic
function and immune cells among participants in a previously reported randomized …

OBJECTIVE In November 2022, teplizumab-mzwv became the first drug approved to delay
the onset of stage 3 type 1 diabetes in adults and children age≥ 8 years with stage 2 type 1 …

Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not
all subjects respond, and the duration of response is limited. Our aim was to determine …

Although most patients with type 1 diabetes (T1D) retain some functional insulin-producing
islet β cells at the time of diagnosis, the rate of further β cell loss varies across individuals. It …

Methods Adults (18–42 years) and adolescents (12–17 years) with type 1 diabetes
diagnosed within 150 days were enrolled, with documented evidence of at least one …

During homeostasis, interactions between tolerogenic dendritic cells (DCs), self-reactive T
cells, and T regulatory cells (Tregs) contribute to maintaining mammalian immune tolerance …

Abstract Type 1 diabetes (T1D) remains an important health problem, particularly in western
countries, where the incidence has been increasing in younger children. In 1986, Eisenbarth …